

Amend the remaining claims and add new claims as follows:

11. (Amended) [The] A heterocyclic compound [of claim 10, wherein the compound of the formula (IIa) is] selected from the group consisting of:

[(1) N-(1-hexyl-5-carboxyethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,]

(1) N-(1-hexyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(2) N-(1-heptyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(3) N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(4) N-(1-nonyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(5) N-(1-decyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(6) N-(1-undecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, and

(7) N-(1-dodecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

[(8) N-(1-hexyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide,

(9) N-(1-hexyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

Patent No. 6,063,806  
Amdt. dated June 27, 2003  
Re: Reissue of USP 6,063,806

(10) N-(1-heptyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide,

(11) N-(1-heptyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(12) N-(1-octyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide, and

(13) N-(1-octyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,]

or a pharmaceutically acceptable salt thereof.

17. (Amended) A pharmaceutical composition comprising an effective amount of a heterocyclic compound of claim [1] 11 or a pharmaceutically acceptable salt thereof.

Add new claims as follows:

20. (New) The heterocyclic compound of claim 11 wherein the compound is in the form of a pharmaceutically acceptable salt which is an acid addition salt with an acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid and nitric acid.

21. (New) The heterocyclic compound of claim 11, which is N-(1-hexyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

22. (New) The heterocyclic compound of claim 11, which is N-(1-heptyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

23. (New) The heterocyclic compound of claim 11, which is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

24. (New) The heterocyclic compound of claim 11, which is N-(1-nonyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

25. (New) The heterocyclic compound of claim 11, which is N-(1-decyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

26. (New) The heterocyclic compound of claim 11, which is N-(1-undecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

27. (New) The heterocyclic compound of claim 11, which is N-(1-dodecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

Patent No. 6,063,806  
Amdt. dated June 27, 2003  
Re: Reissue of USP 6,063,806

28. (New) The heterocyclic compound of claim 11, which is a hydrochloric acid addition salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

29. (New) The heterocyclic compound of claim 11, which is a sulfuric acid addition salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

30. (New) The heterocyclic compound of claim 11, which is a nitric acid addition salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

Patent No. 6,063,806  
Amdt. dated June 27, 2003  
Re: Reissue of USP 6,063,806

Attorney Docket No. 01387RE/HG

**IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE**

Patent Owner: KYOTO PHARMACEUTICAL  
INDUSTRIES, LTD.

Patentee : Shoji KAMIYA et al.

Patent No. : 6,063,806

Issue Date : May 16, 2000

Title : INDOLYL OR INDOLINYL  
DERIVATIVES AND MEDICAL  
USE THEREOF AS ACAT OR  
LIPID PEROXIDATION  
INHIBITORS

Express Mail Mailing Label  
No.: EV 335 579 226 US  
Date of Deposit: June 27, 2003

I hereby certify that this paper is being  
deposited with the United States Postal  
Service "Express Mail Post Office to  
Addressee" service under 37 CFR 1.10 on the  
date indicated above and is addressed to the  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450

  
Laraine Dobies

In the event that this Paper is late filed,  
and the necessary petition for extension of  
time is not filed concurrently herewith,  
please consider this as a Petition for the  
requisite extension of time, and to the  
extent not tendered by check attached  
hereto, authorization to charge the  
extension fee, or any other fee  
required in connection with this Paper  
to Account No. 06-1378.

**PRELIMINARY AMENDMENT IN REISSUE APPLICATION  
AND STATEMENT UNDER 37 CFR 1.173(c)**

COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

S I R :

This is a PRELIMINARY AMENDMENT filed in the above-  
referenced Reissue Application. Please amend the claims as  
follows:

**IN THE CLAIMS:**

Cancel claims 1-10 and 12-16.